TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes

Episode 64: Emily Sims, MD, Pediatric Endocrinologist and Assistant Professor of Pediatrics at Indiana University

In this episode, Dr. Emily Sims joins us to discuss her research focused on diabetes risk factors and treatments to predict or slow diabetes progression. Tune in to learn more about her recent publication on teplizumab, titled "Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals". 

Click here to read the full paper. 

Episode 63: Alex Cogdill, PhD, Director of Business Development and Corporate Strategy at Immunai

In this episode, Alex Cogdill joins us to discuss Immunai. Immunai is an innovative biotech company that works with partners to discover and develop therapies through the integration of machine learning and single-cell multimodal omics at scale. Dr. Cogdill has 13 years of experience in drug discovery and research management; having published >50 scientific articles in the immuno-oncology space with >9,000 citations

Learn more about Immunai here

Episode 62: Wendy Wolf, PhD, VP of Registry and Research at T1D Exchange

In this episode, Wendy Wolf joins us to talk about T1D Exchange and the work they are doing to improve T1D research. T1D Exchange strives to improve outcomes for the T1D population by driving real-world evidence and collaborative change. Their Registry is a long-term research study where individuals volunteer their data to contribute to research evidence. 

Learn more about T1D Exchange here, and the Registry here.  

Episode 61: Peter Senior, PhD, Endocrinologist & Professor at University of Alberta and Kate Farnsworth, Patient Partner at Diabetes Action Canada

In this episode, Peter Senior and Kate Farnsworth join us to discuss the exciting work taking place at Diabetes Action Canada.  Diabetes Action Canada recently launched Connect1d. This platform allows those living with T1D to contribute to research in areas that matter most to them, while also allowing researchers to engage with a diverse range of people living with T1D from across Canada.

 

Interested in learning more about Connect1d?

Visit their website.

Episode 60: José García-Tirado, PhD, Research Associate at the University of Virginia Center for Diabetes Technology

In this episode, Dr. José García-Tirado joins us to discuss his work with the individualization of behavior patterns (including eating and exercise patterns) from CGM, insulin pump, and activity tracker data.

Click on the links below for some of his recent papers. 

Mapping data to virtual patients in type 1 diabetes

Anticipation of Historical Exercise Patterns by a Novel Artificial Pancreas System Reduces Hypoglycemia During and After Moderate-Intensity Physical Activity in People with Type 1 Diabetes

 

Episode 59: Amelia Linnemann, PhD, Assistant Professor at Indiana University School of Medicine

In this episode, Amelia Linnemann joins us to speak about the mechanisms of adaptive stress response in the pancreatic islet. Dr. Linnemann provides us with some insight about a recent publication, Pancreatic beta cell autophagy is impaired in type 1 diabetes.

Learn more about her work here

Episode 58: Qiufu Ma, PhD, Professor of Neurobiology at Harvard University, Dana-Farber Cancer Institute

In this episode, Qiufu Ma joins us to discuss the ongoing research taking place in his lab. Dr. Ma's lab focuses on two lines of research: mapping pain pathways and exploring how acupuncture works. Tune in to hear Dr. Ma discuss one of his recent publications, Somato-Autonomic Reflexes of Acupuncture.

Learn more about Ma Lab here

Episode 57: Gaël McGill, PhD, Founder & CEO at Digizyme, Professor at Harvard Medical School

In this episode, Gaël McGill joins us to discuss ways in which cell and molecular visualization can inform the research and discovery process. Dr. McGill is the founder of Digizyme. Digizyme's mission is to innovate at the intersection of science, technology, art and learning to create accurate and effective visual context for understanding science.

 

Follow the link below for an animation video that explains the fundamentals of SARS CoV-2 membrane binding.

SARS CoV-2 animation

 

To learn more about Digizyme, click here

Episode 56: David Wraith, PhD, Professor of Immunology, Director of the Institute of Immunology and Immunotherapy, University of Birmingham

In this episode, David Wraith joins us to discuss his profound knowledge on autoimmunity and immunotherapy. His research team has revealed mechanisms whereby autoreactive T-cells escape deletion in the thymus and thus appear in the repertoire of all individuals. He also demonstrated that autoreactive T-cells can be silenced by suitable administration of fragments of their protein targets.

Episode 55: Jessica Gibson, MBA, CEO and Co-Founder of Ariel Precision Medicine

In this episode, Jessica Gibson joins us to discuss the latest work at Ariel Precision Medicine. Ariel is a health technology company seamlessly integrating complex genetics into clinical decision-making, empowering doctors and patients to prevent, mitigate or even reverse disease progression. Ariel's initial focus is pancreatic diseases including pancreatitis, diabetes and pancreatic cancer.

Learn more about Ariel Precision Medicine here